Endpoints News
Chiesi signs $1.9B deal to acquire KalVista Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
29 April, 2026
ENDPOINTS at #ASCO26
ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.
presented by mAbxience From lab to life
Glob­al part­ner­ing be­fore the term sheet: de-risk­ing bio­phar­ma deals from day one
top stories
1.
in focus
Bristol Myers reaches a crossroads as a make-or-break year takes shape
2. Chiesi signs $1.9B deal to acquire KalVista and its approved drug
3. AstraZeneca rekindles UK relationship, pledges £300M to expand
4. After Apellis deal, Biogen looks to fill early-stage pipeline
5.
news briefing
Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenue
6. MPM has collected three China drugs so far for its ‘best of both worlds’ strategy
7. Updated: AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacy
8. GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts
9. FDA announces real-time clinical trial data effort, with AstraZeneca and Amgen as test cases
10. Pfizer delays patent cliff for blockbuster heart drug
more stories
• 
Karen Weintraub
.

We’re in the thick of earnings season, and Max Gelman examines Bristol Myers Squibb’s response to the patent expirations of Eliquis and Opdivo. BMS had pinned its hopes on Cobenfy, its schizophrenia drug, but those aspirations have dimmed. Read his take here.
.
Karen Weintraub
Deputy Editor, Endpoints News
.
Chris Boerner, Bristol Myers Squibb CEO (Kevin Dietsch/Getty Images)
Endpoints In Focus
1
by Max Gelman

Bris­tol My­ers Squibb is fac­ing a bit of an iden­ti­ty cri­sis.

CEO Chris Boern­er is near­ly two and a half years in­to his tenure, with...

Read full story
2
by Kyle LaHucik

Chiesi is buy­ing com­mer­cial biotech KalVista Phar­ma­ceu­ti­cals for about $1.9 bil­lion in an ex­ten­sion of the in­dus­try's vig­or­ous spring shop­ping spree.

The Ital­ian phar­ma will...

Read full story
US Pharma and Biotech Summit - May 14, 2026
US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.
3
by Anna Brown

As­traZeneca and the UK gov­ern­ment are back in each oth­er's good graces.

As­traZeneca on Wednes­day said it is lift­ing its UK in­vest­ment pause, with a...

Read full story
4
by Lei Lei Wu

Bio­gen is still look­ing at deals even af­ter ear­mark­ing $5.6 bil­lion to buy Apel­lis Phar­ma­ceu­ti­cals ear­li­er this month.

“Most of what we're go­ing to be...

Read full story
News Briefing: Quick hits from the biopharma web